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Abstract
 .  .We examined the effect of prostaglandin E PGE on bradykinin BK binding, BK-dependent intracellular calcium2 2
 .  .and inositol phosphate IP concentrations and BK mRNA in human glomerular visceral epithelial cells hGVEC . PGE2
 . w3 x10 nM produced a concentration-dependent increase in H -BK specific binding after a lag time of 24 h with a threshold
 .at 0.1 nM. This increase appeared to be mediated exclusively by an increase in BK receptor BKR -2 expression. Scatchard
w3 xanalysis of H -BK saturation binding showed that PGE produced an increase in the receptor site density without a change2
in the apparent dissociation constant. PGE also markedly stimulated cAMP production. This effect was thought to mediate2
the increase in expression of BKR-2 as 8-bromo cAMP and various cAMP-stimulating agents acted similarly. PGE did not2
change the BK-dependent intracellular IP and cytosolic calcium increases. The overexpression of BKR-2 in the presence of3
PGE was associated with an increase in mRNA as shown by the nuclease protection assay without any change in mRNA2
half-life. Cycloheximide, an inhibitor of protein synthesis, enhanced BKR-2 mRNA expression. In conclusion, treatment
with PGE stimulates the synthesis of BKR-2 in hGVEC, possibly by interfering with an inhibitory protein involved in2
BKR-2 transcription. q 1997 Elsevier Science B.V.
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1. Introduction
Glomeruli represent an important site of prostanoid
w xsynthesis in the renal cortex 1 . The predominant
 .product is either prostaglandin E PGE or prosta-2 2
 . w xcyclin PGI according to the species studied 2 .2
Analysis of individual glomerular cell subpopulations
has shown that mesangial cells, endothelial cells and
visceral epithelial cells in culture produce PG and
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 . w xthromboxanes TX 3–5 , although culture condi-
tions induce phenotypic changes in the synthesis
capability of human glomerular mesangial and epithe-
w xlial cells 6 . The glomerular production of
prostanoids, particularly of PGE , is markedly en-2
hanced in experimental models of glomerulonephritis
w x7 . In addition to the resident glomerular cells, the
invading polymorphonuclear leukocytes and
macrophages represent major sources of these prod-
ucts.
PGE exerts a variety of effects in the glomerular2
microcirculation probably by means of its EP andror4
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EP receptors, the activation of which stimulates2
w xadenylate cyclase activity 8 . First, PGE modulates2
 .the constrictor actions of angiotensin II Ang II ,
norepinephrine and vasopressin in cultured mesangial
w xcells 2 . Second, PGE has a vasodilatory action in2
w xthe glomerular afferent arterioles 9 . These in vitro
studies have been confirmed in vivo by the potentiat-
ing effect of cyclooxygenase inhibitors on the Ang
II-dependent reduction in renal plasma flow and
w xglomerular filtration rate 10 . Third, PGE stimulates2
renin release from isolated glomeruli and mesangial
w xcells 11 . Finally, PGE modulates the inflammatory2
response via its inhibitory effect on cell growth and
w xcollagen synthesis 12 and its capacity to stimulate
w xor inhibit the expression of other local mediators 13 .
Kinins are generated in the kidney where they
exert dual functions through the activation of their
 .B2-receptors BKR-2 . They produce contraction of
w xcultured smooth muscle cells and mesangial cells 14
as well as that of endothelium-denuded vessels, but
also are vasodilatory via the release of vasoactive
w xsubstances from the endothelium 15 . There exists a
complex network of interrelations between the vari-
ous glomerular autacoids. Several studies have
demonstrated that the expression of BKR-2 can be
modulated by different agents including cyclic AMP
w x w x16 and interleukin-1 17 . A recent study showed
that, paradoxically, PGE had no effect on BKR-22
expression in rat cultured arterial smooth muscle
cells, despite its associated stimulation of cyclic AMP
w x16 . Our aim was to examine the relationship be-
tween PGE and BKR-2 expression in cultured2
glomerular cells. We chose to study human glomeru-
lar podocytes because these cells possess BKR-2
w xreceptors 18,19 and respond to PGE by markedly2
w xincreasing cyclic AMP production 20 . Our results
demonstrate that long term exposure to PGE stimu-2
lates the synthesis of new BKR-2 receptors associ-
ated with an increase in BKR-2 mRNA. They also
suggest that BKR-2 mRNA expression is under the
control of one or several inhibitory proteins.
2. Methods
2.1. Materials
Materials were from the following sources:
 . w 9x  .bradykinin BK , DesArg BK DBK , prostaglandin
 .  .E PGE , cyclic adenosine monophosphate cAMP ,2 2
actinomycin D, cycloheximide, calphostin and 8-
bromo-cyclic adenosine monophosphate 8-Br-
.  .cAMP were obtained from Sigma St. Louis, MO ;
 . wFura2rAM from Calbiochem San Diego, CA ; pro-
2,3  .3 .  .lyl -3,4 n H BK 2.81 TBqrmmol from the Ra-
 . w125 xdiochemical Center Amersham, UK ; I -cAMP
 . 74 TBqrmmol from ERIA Pasteur Marnes-la-
.Coquette, France ; H89, a protein kinase A inhibitor
 .from Biomol Plymouth Meeting, PA ; incubation
media, culture supplies and 100 bp DNA sequence
ladder from Gibco Life Technologies Eragny,
.  .France ; ribonuclease RNase protection assay kit,
Maxiscript and pT7 RNA 18S template from Ambion
 .Austin, TX ; plasmid vector p Bluescript II from
 . w 32 x Stratagene La Jolla, CA and a P UTP 25
.  .TBqrmmol from ICN Biomedical Orsay, France .
Butaprost was a generous gift of P.J. Gardiner Bayer,
.UK . All other reagents were from Sigma.
2.2. Cell culture
The simian virus-40 transformed human podocyte
 .hGVEC has been previously characterized and
shown to have many characteristics of nontrans-
w xformed parental cells 19 . These cells were studied
between the 20th and 30th passages. They were
cultured in a hormonally defined medium DMEM-
.HAM’s F12, 1:1 vrv supplemented with 2 mM
glutamine, 20 mM HEPES, 30 nM sodium selenate, 5
mgrml transferrin, 5 mgrml insulin, 50 nM dexa-
 .methasone and 2% fetal calf serum FCS . We ini-
tially verified that nontransformed hGVEC respond
to 1 mM BK by an increase in intracellular calcium
w 2qx .Ca similar to that observed with transformedi
hGVEC. Nontransformed hGVEC were prepared from
glomeruli isolated from the cortex of a human ca-
daver kidney judged to be unsuitable for transplanta-
w xtion using a previously published method 4 . They
were cultured in RPMI 1640 medium containing 10%
fetal bovine serum.
2.3. Binding studies
Cell surface binding was measured on confluent
w3 xcells in 12-well plates using H -BK as the ligand
most similar to the natural peptide. Cells were incu-
bated at 378C in an atmosphere of 5% CO –95%2
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room air, with varying concentrations of PGE and2
other agonists for a period of 30 h if not otherwise
.stated in their usual culture medium except for dexa-
methasone which was witheld because its addition
w3 x resulted in decrease of H -BK binding results not
.shown . In some experiments, cells were washed
after 1 h of exposure to PGE and, then, incubated in2
their usual culture medium during the remaining 29
h. Cells were then washed once with 500 ml of a
wash buffer composed of Hank’s solution plus 10
mM HEPES, pH 7.4 and 1 mM 1,10 phenanthroline
and incubated for 18 h at 48C in 0.5 ml of Hank’s
solution supplemented with 10 mM HEPES, pH 7.4,
1 mM 1,10 phenanthroline, 30 mM captopril and 50
mgrml bacitracin. Binding experiments were per-
formed either by saturation analysis with increasing
 . w3 xconcentrations 50–4000 pM of H -BK or with
 . w3 xfixed concentrations 200–500 pM of H -BK. Af-
ter this incubation, the medium was discarded and the
cells were rinsed three times with the wash buffer
and solubilized with 1 M NaOH. Protein measure-
w xment was performed by the Bradford method 21 and
cell-associated radioactivity was counted in a LKB-
 .Beta counter Malmo, Sweden using 8 ml of liquid¨
 .scintillation mixture Aquasafe 300 . Nonspecific
binding was defined as cell-associated binding in the
presence of 1 mM unlabelled BK and was less than
10%. Specific binding was calculated as the differ-
ence between total and nonspecific binding. In all
studies, the results represent the mean"SE for three
separate experiments. In each, three wells of cells
were prepared similarly. Results are expressed as
w3 xfmol H -BK bound per mg of protein or as a
percentage of the control.
2.4. Measurement of cAMP production
hGVEC plated in 12 well plates were incubated at
confluence in serum-free medium containing 0.1 mM
isobutylmethylxanthine for 5 min in the presence or
absence of the following agents: PGE at concentra-2
tions ranging from 10 mM to 0.01 nM, forskolin 10
mM, isoproterenol 1 mM and butaprost 1 mM. At the
end of the incubation period, the supernatant was
discarded. Intracellular cAMP was extracted with an
 .ethanol–formic acid mixture 95r5 vrv and mea-
sured by radioimmunoassay as previously described
w x22 .
( )2.5. Measurement of inositol phosphates IP
After the cells had reached subconfluence, culture
medium was removed and cells were placed in inosi-
tol-deficient Waymouth medium containing 1.1
w3 x  .MBqrml of H -myoinositol 2 ml per well for 48
h at 378C. After 15 min of preincubation with 10
mmolrl LiCl, 10 mmolrl BK was added for 1 min.
The incubation was terminated by rapid aspiration of
the medium and addition of 2 ml ice-cold 5% tri-
chloroacetic acid. Cells were scraped away from the
wells and washed once more with 5% trichloroacetic
acid and the aqueous phase was extracted in dieth-
ylether. Samples were adjusted to pH 7.0 with 50
mmolrl sodium tetraborate and then loaded onto 2
ml Dowex AG1-X8 anion exchange resin columns
 .Bio-Rad . The columns were washed with 10 ml of
water and 10 ml of 5 mmolrl sodium tetraborate. IPs
were then eluted with 10 ml of increasing concentra-
tions of ammonium formate in 0.1 molrl formic acid.
5 ml of each collected fraction was mixed with
scintillation fluid and counted in a beta counter
 .LKB . After correction of quenching, IP values were
expressed as cpm per well.
([ 2q] )2.6. Intracellular free calcium Ca measure-i
ment
Cells were cultured on thin glass microscope cov-
erslips precoated with 0.2% gelatin and were studied
at subconfluence. Cells were loaded with 1.5 mM
Fura 2rAM at 378C for 45 min. For measurement of
fluorescence, each coverslip was placed on the stage
of the inverted microscope and one cell was selected.
The sample was then superfused at a rate of 0.6
mlrmin at 378C with basal medium or with the
solution to be tested. Fura 2 was alternatively excited
at wavelengths of 340 and 380 nm using a 75-W
xenon light source, filters and a chopper PTI Photo-
.scan II System; Kontron . The fluorescence intensi-
 .ties S at 340 nm and L at 380 nm issued from the
selected cell and delimited by mean of an adjustable
w 2qxwindow were measured. Ca was calculated fromi
w 2q x wthe following equation: Ca s K R yi d
.  .x .R r R yR L rL where K s224 nM,min max max min d
RsSrL, and L , L , R and R are L andmin max min max
R values at 0 and saturating concentrations of cal-
cium, respectively. L , L , R and R weremax min min max
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determined by external calibration as previously de-
w xscribed 23 .
2.7. RNase protection assay
A 131 bp DNA fragment of the B receptor was2
w xutilized as previously described 19 . Synthesis of
antisense RNA was carried out using a RNA tran-
 .scription kit Ambion . Incubation with T3 RNA
w 32 x  .polymerase and a P UTP 2.6 MBq was per-
formed at 378C for 1 h. A RNA 18S antisense control
template from Ambion was also incubated with T7
w 32 x  .RNA polymerase and a P UTP 37 KBq under
similar conditions. The RNA probes and total RNA
from hGVEC were hybridized overnight at 458C
using the Ambion kit buffer. Samples were then
treated by RNase and RNase-resistant hybrids were
run on 5% polyacrylamide gel with 8 M urea. Gels
were exposed for 6 to 48 h to a Fuji X-ray film at
808C in the presence of an intensifying screen. Probes
were present in molar excess over the target fragment
in the hybridization reaction. We verified that, under
the conditions employed, the intensity of the pro-
tected fragment was directly proportional to the
amount of complementary RNA in the sample mix-
ture. Quantification of the BKR-2 mRNA band was
performed by densitometry Imager Appligene,
.Pleasanton, CA using 18S RNA as control. To test
the effect of PGE on mRNA expression, the cells2
were incubated in the presence of 10 nM PGE for 1,2
2, 4, 6, 18 and 24 h prior to the extraction of RNA.
To estimate the effect of PGE on mRNA stability,2
cells were incubated for 18 h in the presence or
absence of 10 nM PGE and then were exposed to2
actinomycin D at 2 mgrml to block further RNA
synthesis, and RNA was extracted after 1, 2, 3 and 4
h. In order to investigate the effect of the protein
synthesis inhibitor, cycloheximide, on the upregula-
tion of the BKR-2 transcript by PGE , cells were2
incubated for 10 h in the presence or absence of 10
nM PGE with or without cycloheximide at 0.52
mgrml.
2.8. Statistical analysis
Data are presented as means"SE. Statistical com-
parisons of the means were made using the Student’s
t-test or analysis of variance.
3. Results
[3 ]3.1. Effect of PGE on H -BK binding to human2
glomerular ˝isceral epithelial cells
w3 xIn the presence of 10 nmolrl PGE , H -BK2
binding reached 170.6"10.3% baseline value: 24.8
. "1.0 fmolrmg at 24 h and 194.5"31.8% base-
.line value: 23.9"1.3 fmolrmg at 30 h. No increase
 .was observed after 3 or 6 h of incubation Fig. 1 . To
examine whether a short exposure to PGE also2
modulated the level of BK receptors measured 30 h
later, we compared the results obtained with cells
exposed permanently to 1 mM PGE over the total2
period of incubation and cells treated only during 1 h.
w3 xH -BK binding increased under both conditions, but
significantly less in cells which had been treated
briefly 154"3.5% and 200"1.7% of baseline for
the experiments with a short and a long exposure to
.PGE , respectively, P-0.05 . A dose–response2
analysis performed with a 30 h incubation revealed
that the threshold was 0.1 nmolrl and a plateau of
244.3"8.5% of baseline was reached at 10 nmolrl
w3 xFig. 1. Time course of PGE effect on H -BK binding to2
hGVEC. Cells were incubated for 3, 6, 24, 30 and 48 h in the
 .  .presence PGE or absence control of 10 nM PGE , before2 2
w3 xbeing placed for 18 h at 48C in the presence of H -BK. Specific
binding is shown. Each bar represents the mean"SE for three
separate experiments of three wells each. ) Represents a P-value
-0.05 and )) indicates a P-value-0.005.
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of PGE . There was then a slight and progressive2
w3 xdecrease in H -BK binding reaching 217.1"14.7%
 .of baseline at 10 mmolrl Fig. 2A . Examination of
the acute effects of PGE on cyclic AMP production2
 .with an incubation period of 5 min revealed a 1.9
fold stimulation at a threshold of 0.1 nmolrl and a
200 fold increase at 10 mmolrl PGE . There was no2
demonstrable plateau up to the latter concentration
 .Fig. 2B . To determine whether the effect of PGE2
was dependent upon the SV-40-transformed pheno-
w3 xtype, we studied nontransformed cells. H -BK bind-
ing under the same conditions 18 hours at 48C in the
w3 x .presence of 700 pM H -BK was increased after
incubation of the cells for 30 h with 10 nM or 100
nM PGE 157.3"24.6 and 211.1"37.1% of con-2
.trol, respectively, ns8, P-0.05 versus control .
To verify that the additional receptors observed
after PGE treatment demonstrated the pharmacologi-2
cal characteristics of BKR-2, we performed competi-
tive binding experiments with cells which had been
treated for 30 h with 10 nmolrl of PGE . As in2
w3 xuntreated cells, no displacement of bound H -BK
was observed at increasing concentrations of De-
9  .sArg -BK, a BKR-1 agonist Fig. 3 . Thus PGE2
treatment resulted in the induction of BKR-2, but not
of BKR-1.
w3 xTo determine whether the PGE -mediated H -BK2
binding increase was due to an increase in B or amax
decrease in K , we performed saturation bindingD
 . w3 xexperiments Fig. 4A . Bound H -BK increased
progressively with increasing concentrations of the
tracer until a plateau was reached at 1 nmolrl.
 .Scatchard analysis of the data ns3 demonstrated
that BK binds to a single class of receptors with a
mean B of 73.4"11.6 fmolrmg cell protein andmax
 .a K of 0.24"0.04 nmolrl Fig. 4B . Pre-exposureD
of hGVEC to 10 nmolrl of PGE for 30 h resulted in2
a marked increase in BK binding which was due to
an increase in the BK receptor B 127.0"20.8max
. fmolrmg cell protein with no change in K 0.19"D
.0.03 nmolrl . Comparison of the regression lines
obtained in each experiment from the control and
experimental data indicated that the difference be-
 . tween B abscissa intercepts was significant Pmax
.-0.05 . This change in receptor density did not
simply reflect a change in hGVEC protein content,
because there were no significant differences in pro-
teins after a 30 h exposure of hGVEC to either
 . w3 xFig. 2. A Effect of concentration of PGE on H -BK binding2
to hGVEC. Cells were pre-incubated for 30 h in the presence of
0.01 nM to 10 mM PGE , before being placed for 18 h at 48C in2
w3 xthe presence of H -BK. Only specific binding is shown. Each
bar represents the mean"SE for three separate experiments of
three wells each. C indicates control. ) Represents a P-value-
))  .0.05 and indicates a P-value-0.005. B Effect of concen-
tration of PGE on cellular production of cAMP. Cells were2
incubated for 5 min in Waymouth’s medium containing 1 mM
isobutylmethylxanthine and concentrations of PGE ranging from2
0.01 nM to 10 mM. cAMP measurement was then performed by
radioimmunoassay. Each bar represents the mean"SE of six
separate experiments. C represents control. ) Represents a P-
value-0.05 and )) indicates a P-value-0.005.
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w3 xFig. 3. Competitive inhibition of H -BK binding to hGVEC in
presence of increasing concentrations of unlabelled BK or Des
Arg9-BK. Confluent cells in 12-well plates were pre-incubated
 .  .for 30 h at 378C in the presence PGE or absence control of2
10 nM PGE . Cells were then placed at 48C for 18 h for binding2
w3 xin the presence of 700 pmol H -BK and increasing concentra-
9  .tions of either Des Arg -BK or BK 100 pM to 1 mM . C
represents the two controls: unexposed and exposed to PGE . All2
results are expressed as percents of the control unexposed to
PGE . The means"SE of two separate experiments of four wells2
each are shown.
 .control medium 551"111 mgrml or 10 nmolrl of
 .PGE 387"30 mgrml; ns18 .2
w3 xTo determine whether the PGE -induced H -BK2
binding increase was cyclic AMP-mediated, BK bind-
ing was measured following incubation with bu-
taprost, a PGE agonist specific to the adenylate2
w xcyclase-linked EP-2 type PGE receptor 24 . We2
also examined several other agonists: 8-bromo cyclic
AMP, a cell permeant analogue of cyclic AMP;
forskolin, an activator of the catalytic moiety of
adenylate cyclase; isoproterenol, a b-adrenergic ago-
nist and isobutylmethylxanthine, a phosphodiesterase
inhibitor. All of these products stimulated cyclic AMP
w3 xproduction acutely, as well as H -BK binding after
 .30 h of incubation Fig. 5A and B . There was no
correlation between the magnitudes of increase in
w3 xH -BK binding and cyclic AMP production, respec-
tively. For example, 1 mmolrl of butaprost and 10
mmolrl of forskolin were equally potent in stimulat-
w3 xing H -BK binding, whereas butaprost was much
more potent than forskolin in terms of cAMP produc-
tion. On a molar basis, PGE was the most efficient2
w3 x of all the products tested for H -BK binding Fig.
.5A . In particular, PGE was more potent than its2
EP-2 type agonist. The maximum response with bu-
 .taprost 167"8% of baseline reached at 1 mM was
lower than that obtained with 0.01 mM PGE 215"2
 . w3 xFig. 4. A Saturation binding study of H -BK binding to
hGVEC in presence or absence of PGE . Cells were incubated2
 .  .for 30 h in the presence PGE or absence control of 0.01 mM2
PGE and then placed at 48C for 18 h in the presence of2
w3 x  .increasing concentrations of H -BK 50 to 4000 pM . Satura-
tion was attained at approximately 2000 pM in both cells exposed
 .and unexposed to PGE . B Scatchard’s transformation of the2
data revealed two parallel lines, the K ’s of which were notD
significantly different. Two additional studies were performed.
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.8% of baseline and the threshold which was 0.1 nM
 .for PGE 130"3% was observed only at 10 nM2
 .for butaprost 122"4% .
Since cyclic AMP effects depend upon protein
 . w3 xFig. 5. A Effects of selected agonists on H -BK binding to
hGVEC. Cells were pre-incubated for 30 h in the presence of
0.01 mM PGE , 1 mM butaprost, 10 mM forskolin, 1 mM2
isoproterenol, 100 mM 8-bromo-cAMP or 100 mM isobutylmeth-
w3 xylxanthine, before 18 h of H -BK binding. Only specific bind-
ing is shown. Each bar represents the mean"SE for three
 .separate experiments of three wells each. C indicates control. B
Effects of selected agonists on cellular cAMP production. Cells
were incubated for 5 min in medium containing 100 mM
isobutylmethylxanthine in the presence of 10 nM PGE , 1 mM2
butaprost, 10 mM forskolin or 1 mM isoproterenol. cAMP
measurement was then performed by radioimmunoassay. Each
bar represents the mean"SE of six separate experiments. C
indicates control. ) Indicates a P-value-0.05 and )) a P-value
-0.005.
w3 xFig. 6. Effects of selected inhibitors on H -BK binding to
hGVEC. Cells were pre-incubated for 24 h in the presence or
absence of 10 nM PGE , with or without the addition of 50 nM2
w3 xcalphostin or 20 mM H89, before 18 h of H -BK binding. Only
specific binding is shown. Each bar represents the mean"SE for
three separate experiments of three wells each. C represents
control. † Indicates a P-value-0.05 and †† a P-value-0.005 in
comparing the effect of each inhibitor with its control. ) Indi-
cates a P value-0.05 and )) a P-value-0.005 in comparing
the effect of H89 plus PGE with that of PGE alone.2 2
 .kinase A PKA stimulation, H89, a specific PKA
inhibitor, was utilized to determine if the PGE -in-2
w3 xduced H -BK binding increase was modified. We
also examined the effect of calphostin, a PKC in-
 .hibitor Fig. 6 . Neither antagonist was able to en-
tirely suppress the stimulatory effect of PGE . How-2
ever, whereas there was no difference between
w3 xPGE -dependent H -BK binding with and without2
calphostin treatment 187.6"4.3 versus 196.6"
.10.9% of control, respectively , H89 treatment re-
sulted in a slight but significant decrease 157.2"
10.1 versus 202.0"17.3% of control, respectively;
.P-0.05 .
3.2. Effect of PGE on BK-dependent increased IP2
turno˝er
Stimulation of the G protein-coupled BKR-2 in
hGVEC is associated with phospholipase C activation
and an increase in IP production by hydrolysis of
inositol phospholipids. IP which is initially formed3
from phosphatidylinositol 4,5-biphosphate break-
down, undergoes phosphorylation and dephosphoryla-
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w 2qx  .Fig. 7. Ca responses of hGVEC to 0.1 mmolrl BK. Cells had been incubated for 30 h either under control conditions A or in thei
 .presence of 10 nmolrl PGE B . This experiment was repeated 24 times with similar results.2
tion reactions that result in the formation of a variety
of compounds. Therefore, we examined the effect of
PGE on this response to 10 mmolrl BK. No differ-2
ence was observed between the untreated cells and
the cells pretreated with PGE for IP 2006"752 1
.versus 1866"69 cpm per well, respectively and IP3
232"16 versus 256"15 cpm per well, respec-
.tively . There was however a small but significant
increase in IP formation in the cells that had been2
pretreated with PGE 981"30 versus 794"63 cpm2
.per well; P-0.01, ns24 .
3.3. Effect of PGE on the BK-dependent increase of2
[ 2q]Ca i
To determine whether PGE -induced augmentation2
in BKR-2 expression had an influence upon BK-gen-
erated intracellular calcium currents, intracellular cal-
cium signals produced by 100 nM of BK were mea-
sured in individual cells incubated for 48 h at 378C in
 .the presence or absence of 10 nM PGE Fig. 7 . A2
high degree of cell-to-cell variability in BK-depen-
dent intracellular calcium currents was found using
this technique, but no difference in the amplitude of
intracellular calcium peaks was uncovered: in PGE -2
treated cells the mean was 405.83"88.22 nM versus
418.75"109.95 nM in non-treated cells ns24,
.Ps0.928 .
3.4. Effect of PGE on BKR-2 mRNA expression2
hGVEC were incubated in the presence or absence
 .of PGE 10 nM for 2–24 h. In the presence of2
PGE there was a progressive increase over time in2
the abundance of BKR-2 mRNA. Using 18S mRNA
as an internal control, we observed that the ratio of
BKR-2 mRNA to 18S mRNA reached 2.6"0.4 n
.  .s4 after 24 h of incubation with PGE Fig. 8 .2
Since a change in the abundance of BKR-2 mRNA
could result from an alteration of either the transcrip-
Fig. 8. Time-course of changes in BKR-2 mRNA values in
hGVEC which had been or not pre-incubated with 0.01 mM
PGE for the indicated periods of time. mRNA values were2
determined by nuclease protection assay. 18S mRNA was used as
an internal control. The autoradiograms were scanned using a
densitometer. BKR-2 mRNA values are expressed relative to 18S
mRNA. The data shown in the lower part are the average"SE of
four experiments.
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tion rate or the degradation rate of the mRNA, the
half-life of the BKR-2 mRNA was examined by
inhibiting mRNA transcription with actinomycin D.
After incubating the cells with 10 nM PGE for 18 h,2
actinomycin D was added at a final concentration of
2 mgrml and the disappearance of BKR-2 mRNA
over time was measured by the nuclease protection
 .assay Fig. 9 . BKR-2 mRNA from cells treated with
PGE for 18 h had the same average half-life as that2
seen in control cells 186"29 and 211"50 min,
.respectively; ns3 .
To determine whether induction of BKR-2 was a
primary effect or required intermediate protein syn-
thesis, we examined the effect of treating the cells
with 0.5 mgrml of cycloheximide for 6 and 10 h.
Cycloheximide increased BKR-2 mRNA at 6 h and
the effect persisted up to 10 h. An incubation time of
10 h was selected since there was a significant stimu-
 .latory effect of both PGE 10 nM and cyclohex-2
imide at this time. When cells were exposed simulta-
neously to these two agents, an additive effect was
Fig. 9. Estimation of the half-life of BKR-2 mRNA in hGVEC
treated or not for 18 h by 0.01 mM PGE . Actinomycin D 22
.mgrml was added to culture medium to block transcription and
total RNA was prepared from cells after various times of incuba-
tion. The decay of BKR-2 mRNA values was detected by nucle-
ase protection assay. The autoradiograms were scanned using a
densitometer. A representative experiment out of three is shown.
 .Fig. 10. Effect of cycloheximide cyclo and of PGE alone or in2
combination on BKR-2 mRNA expression. mRNA values were
determined by nuclease protection assay after a 10 h incubation
period of hGVEC with the agents to be tested. 18S mRNA was
used as an internal control. The autoradiograms were scanned
using a densitometer. BKR-2 mRNA values are expressed rela-
tive to 18S mRNA. The data shown in the lower part are the
average"SE of four experiments.
obtained. Indeed, the ratio of BKR-2 to 18S mRNA
signal measured under basal conditions increased by
370% with cycloheximide alone, 328% with PGE2
alone and 767% with cycloheximide and PGE in2
 .combination Fig. 10 .
4. Discussion
These studies demonstrate that BKR-2 mRNA and
receptor number are regulated by PGE and its sec-2
ond messenger cAMP. This was demonstrated by
exposing hGVEC to PGE , to butaprost, a PGE2 2
analogue specific to adenylate cyclase-linked EP2
receptors, as well as to other agents that increase the
concentration of intracellular cAMP. The upregula-
w3 xtion of H -BK binding sites in vitro was reproduced
by all of the agents tested, including forskolin, 8-
bromo-cAMP, isobutylmethylxanthine and isoprote-
renol. This suggests a central role for the involvement
of cAMP, as opposed to other drug-related effects. It
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is possible that PGE activated other receptors than2
w xEP . Indeed, Breyer et al. 25 showed high expres-2
sion of EP mRNA in human glomeruli using in situ4
hybridization whereas there was no signal for EP2
mRNA. However, the stimulation of cyclic AMP
production by butaprost with a potency close to that
of PGE suggests that human podocytes also contain2
EP receptors. Of note, PGE was much more potent2 2
w3 xthan butaprost with regard to H -BK binding. This
suggests a dual mechanism cAMP-independent and
.cAMP-dependent for PGE . In favor of this hypoth-2
esis, is also the fact that a short exposure to PGE2
sufficient to stimulate cAMP production resulted in a
w3 xsmaller increase of the H -BK binding sites 30 h
later than a permanent exposure to PGE over this2
whole period. The question of the role of such a
cAMP-independent mechanism must be addressed in
further studies. We have recently characterized BKR-
w x2 receptors in hGVEC 19 and we demonstrated the
absence of BKR-1 receptors. Since the BKR-1 recep-
tors are not often expressed constitutively, it was
necessary to determine whether the newly synthe-
sized sites were BKR-1 receptors. Since the supple-
w3 xmentary H -BK binding sites were displaced by
unlabelled BK but not by DesArg9BK, a BKR-1
agonist, it does not appear that these new sites are
BKR-1 receptors.
w3 xEnhanced H -BK binding to BKR-2 was due to
an increase in the density of the receptor sites without
changing affinity. In addition, the effect of PGE was2
not inhibited by PKC inhibitors, indicating that
PKC-mediated phosphorylation of the receptor was
not implicated in changing its binding activity. Taken
together, these results suggested that PGE affected2
transcription or mRNA stability.
A marked increase in BKR-2 mRNA expression
following PGE stimulation was demonstrated using2
the nuclease protection assay technique. Treatment
with PGE led to an increase of BKR-2 mRNA2
abundance by 6 h which was still present at 24 h. The
w3 xreceptor number as measured by H -BK binding
increased later: receptor site density was significantly
increased at 24 h and reached a peak at about 30 h.
The elevated BKR-2 mRNA levels were not due to a
decreased rate of degradation as demonstrated by the
fact that the half-lives of the BKR-2 mRNA did not
differ significantly under control conditions and after
treatment with PGE . They were both approximately2
 .3 h which is slightly greater than the value 2.5 h
w xrecently reported by Sakaue et al. 26 for the a 2A
adrenergic receptor mRNA which is also transcrip-
tionally regulated by cAMP. The absence of a change
in mRNA stability is most consistent with a regula-
tory effect of PGE at the level of BKR-2 mRNA2
transcription in hGVEC under the experimental con-
ditions used.
A lag in the time between a stimulus and a tran-
scription event frequently results from the involve-
ment of an intermediate protein. Our data provides
evidence for this hypothesis since cycloheximide
alone stimulated BKR-2 mRNA expression. This sug-
gested that, under basal conditions, an inhibitory
protein negatively controlled the transcription of the
BKR-2 gene. Such superinduction of a gene encoding
a peptide hormone receptor by protein synthesis in-
hibitors has been described, although the mechanisms
responsible for this effect are still not completely
w xelucidated 27,28 . An additive effect was obtained
when hGVEC were exposed simultaneously to PGE2
and cycloheximide. This indicates that these two
agents act via distinct mechanisms and also suggests
that the PGE effect does not require protein synthe-2
sis since it occurred in the presence of cyclohex-
imide. This suggests that PGE acts by attenuating2
the activity of this inhibitory intermediate protein
rather than via the binding of CRE binding protein or
AP-2 to the promoter region of the BKR-2 gene. In
agreement with this conclusion, no transcription fac-
tor binding sites have been identified yet in the
w xregulatory region of the human BKR-2 gene 29 .
Possibly, cAMP via PKA activation acts negatively
on the activity of the unknown intermediate protein
controlling BKR-2 gene transcription. Of interest, H
89, a PKA inhibitor, inhibited slightly but signifi-
w3 xcantly PGE -dependent H -BK binding, suggesting2
that PKA activation and the subsequent phosphoryla-
tion of an intermediate protein are essential steps in
PGE stimulation of BKR-2 expression. Such an2
hypothesis requires further experiments in order to be
confirmed.
Our results differ in part from those recently re-
ported by Dixon in another cell type in vitro, arterial
w xsmooth muscle cells 16 . In his preparation, cholera
toxin, forskolin and isobutylmethylxanthine, but not
isoproterenol or PGE , increased BK receptor bind-2
ing and calcium mobilization. The effect of the cyclic
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AMP-stimulating agents was blocked by protein syn-
thesis inhibitors, suggesting that cAMP enhanced the
synthesis of new BK receptors or an intermediate
protein or transcription factor. The absence of an
effect of PGE may be the result of the absence of2
EP-2 receptors in the cultured arterial smooth muscle
cells studied.
Activation of BKR-2 receptors in hGVEC results
w 2qxin increased inositol phosphate turnover and Ca i
w xstimulation 18,19 . In addition to measuring changes
w3 xin H -BK binding sites and BKR-2 mRNA, we also
examined the functional consequences of BKR-2 up-
regulation. The increase in BKR-2 receptors and
mRNA after PGE treatment was not associated with2
w 2qxan increase in Ca stimulation. There was only ai
slight but significant increase in IP formation. Such2
an effect of BK has been reported as a long term
w xeffect by Dixon 16 in rat arterial smooth muscle
cells that had been pretreated with cAMP. This sug-
gests that PGE via cAMP formation could enhance2
the dephosphorylation of IP to IP or alter the3 2
hydrolysis of phosphatidylinositol phosphate by
phospholipase C. The lack of increase in BK-depen-
w 2qxdent Ca transients in spite of the increase ini
BKR-2 in PGE -treated cells, suggests that untreated2
cells already possess maximum BK-dependent cal-
cium release so that further increases in receptor
density do not result in any further stimulation of
w 2qxCa . The increased conversion of IP to IP couldi 3 2
contribute to counterbalancing the high BKR-2 num-
ber by decreasing calcium release from intracellular
stores.
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